top of page
  • Jonathan Poyer

2024 Doubling the Number of Biotech Transactions from 2023. The Index Waits to Respond

Chair Powell's comment that additional rate hikes were unlikely led to a violent rally in the S&P Select Biotech Index as the 10-year yield retreated back down below 450 bps. The S&P Select Biotech Index rallied back to the 50-day moving average and started the week largely holding those gains despite a slew of negative SMID cap clinical data updates highlighting the strong influence of macro considerations

Week Ending May 3rd, 2024:

  • Biotech: 5 Transactions (1 Follow-on, 1 PIPE, and 3 RDs) totaling just under $400M

  • Med Tech: No current week transactions

2024 YTD:

  • 138 Biotech transactions totaling just over $23 Billion v. 2023 YTD: 53 Biotech transactions totaling just under $8 Billion

  • 4 Med Tech transactions totaling just over $500 Million v. 2023 YTD: 6 Med Tech transactions totaling just over $400 Million

Private Transactions:

  • Biotech: 87 US Transactions / 36 European Transactions

  • Med Tech: 46 US Transactions / 21 European Transactions

Notable Transactions:

  • Novartis acquired Mariana Oncology for $1B

  • Ono Pharmaceutical acquired Deciphera Pharmaceutical for $2.4B or $25.60/share

  • Incyte acquired Escient Pharmaceuticals for $750M

  • Vertex acquired Alpine Immune Sciences for $4.9B or $65/share

  • Genmab acquired Profound Bio for $1.8B

16 views0 comments


bottom of page